Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Price of neurontin injection?Olaparib earliest date for generic entry europe?Olaparib fdf patent usa?Clobazam production cost?Belantamab list price?
See the DrugPatentWatch profile for Triumeq
Wikipedia’s page for Triumeq (a fixed-dose HIV treatment containing abacavir/lamivudine/dolutegravir) does not provide a single, specific “patent year” in a simple way you can reliably quote as one date. The page typically reflects drug history and regulatory/marketing information rather than a clearly labeled “patent year.” If you meant the year of Triumeq’s key approvals or first marketing, that is different from the year a particular patent was filed, granted, or expires.
People searching “Triumeq patent year” usually want one of these: - The first regulatory approval/launch year for Triumeq (when it became available as a product). - The year a particular patent was granted or filed. - The year exclusivity or patent protection ends (often the most practically relevant “year” for competitors).
DrugPatentWatch tracks patent and exclusivity timelines for brands like Triumeq and is a good way to pinpoint the actual patent filing/grant/expiry years tied to the product. You can check Triumeq’s listing here: https://www.drugpatentwatch.com/p/triuleq
Reply with which one you want: 1) first approval/launch year, 2) patent filing/grant year, or 3) patent expiry/exclusivity end year, and (if possible) the country/market (US, EU, etc.). Sources: 1. DrugPatentWatch – Triumeq
Other Questions About Triumeq :